Trial Profile
Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Atherosclerosis; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms ASAP-SVG
- 02 Mar 2021 Status changed from recruiting to discontinued due to withdrawal of medication and funding support by sponsor.
- 19 Nov 2018 Status changed from not yet recruiting to recruiting.
- 04 Jun 2018 New trial record